A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC
Launched by THE FIRST AFFILIATED HOSPITAL OF GUANGZHOU MEDICAL UNIVERSITY · Jan 9, 2025
Trial Information
Current as of July 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new treatment approach for patients with resectable non-small cell lung cancer (NSCLC), which is a type of lung cancer that can still be surgically removed. Researchers want to see how effective and safe a combination of a medication called adebrelimab with chemotherapy (and possibly another drug called bevacizumab) is for this condition. The trial is open to adults aged 18 to 65 who have not yet received any prior treatment for their cancer and have a good level of health.
If you or someone you know is considering participating in this trial, you should be aware that participants will receive the study treatment and will be monitored closely for any side effects. To be eligible, patients must have a specific type of lung cancer that can be operated on and must meet certain health criteria, including having enough lung function for surgery. It’s important to note that patients with other types of lung cancer or those who have previously received certain cancer treatments may not qualify to participate. This trial is currently recruiting participants, and being part of it could help researchers learn more about effective treatments for lung cancer.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Resectable NSQ NSCLC
- • Age 18-65 years
- • male or female
- • ECOG 0-1
- • Subjects have not received surgery, chemotherapy, radiotherapy and biological treatment of treatment-naive non-squamous non-small cell lung cancer
- • Subjects must have adequate pulmonary function for the intended pneumonectomy;
- Exclusion Criteria:
- • SCLC or SQ NSCLC
- • previously used anti-PD1, anti-PDL1, anti-CTLA4 antibodies, etc.
- • patients who have previously used anti-angiogenic drugs;
- • allergic to any component of the study drug or chemotherapy drugs
- • patients with any severe and or uncontrolled disease
About The First Affiliated Hospital Of Guangzhou Medical University
The First Affiliated Hospital of Guangzhou Medical University is a leading clinical research institution located in Guangzhou, China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative research. As a comprehensive teaching hospital, it integrates clinical practice, education, and research, fostering a multidisciplinary approach to healthcare. The hospital is equipped with state-of-the-art facilities and a team of experienced professionals dedicated to conducting high-quality clinical trials across various therapeutic areas. By leveraging its extensive expertise and resources, the First Affiliated Hospital aims to contribute significantly to the development of new treatments and therapies, enhancing health outcomes for patients both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Guangzhou, , China
Patients applied
Trial Officials
Jianxing He
Principal Investigator
The First Affiliated Hospital of Guangzhou Medical University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported